ClinicaliQ Trial Snapshot
- Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK) — Recruiting • Phase III • Rheumatology • NCT07116967.
- Review the linked registry entry for study design, population, endpoints, and operational status.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
A study to evaluate the long-term safety of Deucravacitinib versus Ustekinumab in participants with psoriasis Conditions: Plaque Psoriasis Interventions: Deucravacitinib, Ustekinumab Lead Sponsor: Bristol-Myers Squibb Planned Enrollment: 3040 participants